# 7. 510(k) SUMMARY

# Contact Information

David M. Lyerly   
Vice-President, Research & Development TECHLAB, Inc.   
2001 Kraft Drive   
Corporate Research Center   
Blacksburg, VA 24060

Phone: 540-953-1664 FAX: 540-953-1665 Email: dlyerly@techlab.com

# Date Prepared

December 20, 2005

# Product and Trade Name

C. DIFF QUIK CHEKTM

# Classification

21 CFR 866.2660

# Predicate Devices

C. difficile Culture media such as cycloserine - cefoxitin fructose agar (CCFA) is available commercially from various sources.   
• C. DIFF CHEKTM - 60 (K030992) - TECHLAB\*, Inc. (Blacksburg, VA)   
• C. DIFF CHEKTM - 30 (K030991) - TECHLAB®, Inc. (Blacksburg, VA)   
• BD CULTURETTETM CDTTM (K870864) - Becton, Dickinson and Company (Franklin Lakes, NJ)   
• Triage® Micro Clostridium difficile Panel (K974881) - Biosite Incorporated (San Diego, CA)   
• ImmunoCard® C. difficile EIA (K924979) - Meridian Bioscience, Inc. (Cincinnati, OH)

# Intended Use

The C. DIFF QUIK CHEKTM test is a rapid membrane enzyme immunoassay for use as a screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile disease. The test does not distinguish toxigenic from nontoxigenic strains of C. difficile. With the use of additional tests that detect $C .$ difficile toxins, the test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. dificile tests, results should be considered in conjunction with the patient history.

# Device Description

The C. DIFF QUIK CHEK TM test uses antibodies specific for glutamate dehydrogenase (GDH) of C. difficile. The device contains a Reaction Window with two lines of immobilized antibodies. The test line ("T") contains antibodies against C. difficile GDH. The other, representing a control line $( ^ { 6 4 } \mathrm { C } ^ { 7 } )$ ,contains anti- $\mathbf { I g G }$ antibodies. The Conjugate consists of antibody to GDH coupled to horseradish peroxidase. To perform the test, the fecal specimen is diluted with Diluent, and Conjugate is added to the diluted sample. The diluted sample

conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, any GDH in the sample binds to antibodyperoxidase conjugate. The antigen-antibody complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-GDH antibody in the line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After up to a 10-minute incubation, the "T" reaction is examined visually for the appearance of a blue line. A blue line indicates a positive test. A positive "C" reaction, indicated by a blue line, confirms that sample and all reagents were added in proper sequence and volume, that reagents were active at the time of performing the assay, and that proper sample migration occurred.

Comparative Information of Equivalent Devices   

<table><tr><td rowspan=1 colspan=1>Culpalatlve lll</td><td rowspan=1 colspan=1>0lhation ol</td><td rowspan=1 colspan=1>Duulvaicnt leviet</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>510(k)Numbers</td><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Materials</td><td rowspan=1 colspan=1>TargetPopulation</td></tr><tr><td rowspan=1 colspan=1>C. DIFF QUIKCHEK™M test</td><td rowspan=1 colspan=1>Subject tothis 510(k)</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>Rapidmembrane</td><td rowspan=1 colspan=1>Highly specificantibodiesagainst C.difficile GDH</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>C. difficilePresumptivebacterial culture</td><td rowspan=1 colspan=1>Used before1976,510(k) notavailable.</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>Bacterialculture</td><td rowspan=1 colspan=1>Specificselectivemedia, CCFAplates and CCBHIbb broth</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>C. DIFF CHEKTM-60</td><td rowspan=1 colspan=1>K030992</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Highly specificantibodiesagainst C.difficile GDH</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>C. DIFF CHEKTM- 30</td><td rowspan=1 colspan=1>K030991</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Highly specificantibodiesagainst C.difficile GDH</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>BDCULTURETTETMCDTTM</td><td rowspan=1 colspan=1>K870864</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>Latexagglutination</td><td rowspan=1 colspan=1>Antibodiesagainst C.difficile GDHand otherproteins</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>Triage® Micro C.difficile Panel,GDH portion</td><td rowspan=1 colspan=1>K974881</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>Flowthroughmembranetest</td><td rowspan=1 colspan=1>Highly specificantibodiesagainst C.difficile GDH</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr><tr><td rowspan=1 colspan=1>ImmunoCard C.difficile EIA</td><td rowspan=1 colspan=1>K924979</td><td rowspan=1 colspan=1>Detection of C.difficile organismin fecalspecimens</td><td rowspan=1 colspan=1>Lateral flowmembranetest</td><td rowspan=1 colspan=1>Highly specificantibodiesagainst C.difficile GDH</td><td rowspan=1 colspan=1>Personssuspected ofhaving C.difficile disease</td></tr></table>

a, CCFA, cycloserine - cefoxitin fructose agar plates b, CC-BHI, cycloserine - cefoxitin brain-heart infusion liquid media

# Summary of Performance Data Clinical Accuracy

The Tables below show a summary of the clinical performance of the C. DIFF QUIK $C H E K ^ { \mathrm { { T M } } }$ test. Results from 3 studies are included in the summary. The discrepant samples generated from the C. DIFF QUIK CHEK TM test and the presumptive bacterial culture assay were resolved using a PCR assay, an ELISA for the antigen, or a membrane test for the antigen, as described in the individual studies. The protocols are included in Appendix A and D. The results show that the C. DIFF QUIK CHEKTM test exhibited a correlation of $9 2 . 6 \%$ with presumptive bacterial culture. When discrepant results were resolved by PCR, the correlation was $9 6 . 9 \%$ .

# Clinical Performance Comparing C. DIFF QUIK CHEK™M Test to Presumptive Bacterial Culture

<table><tr><td rowspan=1 colspan=1>n=979</td><td rowspan=1 colspan=1>resumptive BacterialCulture positive.</td><td rowspan=1 colspan=1>Presumptive BacterialCulture negative</td></tr><tr><td rowspan=1 colspan=1>C. DIFF QUIK CHEK™M positive</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>56</td></tr><tr><td rowspan=1 colspan=1>C. DIFF QUIK CHEKTM negative</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>701</td></tr></table>

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>95% Confidence Limits</td></tr><tr><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=1>92.8%</td><td rowspan=1 colspan=1>88.3% - 95.7%</td></tr><tr><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>90.4% - 94.3%</td></tr><tr><td rowspan=1 colspan=1>Predictive Negative Value</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>96.3% - 98.7%</td></tr><tr><td rowspan=1 colspan=2>Correlation</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>91.7% - 93.4%</td></tr></table>

Twenty-nine of the 56 apparent false positive samples were positive by another GDH test, and were considered true positive. Twenty-seven remained false positive. Thirteen of the 16 apparent false negative samples were negative by another GDH test, and were considered true negative. Three remained false negative. The summary is presented below.

# Clinical Performance of C. DIFF QUIK CHEK™M Test versus Bacterial Culture Assay after Resolution by another GDH Test

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Resolved Bacteria</td><td rowspan=1 colspan=1>Resolived Bacteral</td></tr><tr><td rowspan=1 colspan=1>C. DIFF QUIK CHEK™M positive</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>C. DIFF QUIK CHEK™M negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>714</td></tr></table>

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>95% Confidence Limits</td></tr><tr><td rowspan=1 colspan=1>Predictive Negative Value</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>98.7% - 99.9%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=1>96.5% - 97.2%</td></tr></table>

# Analytical Sensitivity

The test was consistently positive at a concentration of $0 . 4 ~ \mathrm { { n g / m L } }$ for GDH.

# Cross-Reactivity

The specificity of the C. DIFF QUIK CHEK TM test was evaluated by examining the reactivity of a wide range of common intestinal bacteria and intestinal pathogens in the assay. For the analysis, the organismns were grown to early stationary phase (>108 CFU/ml). The viruses were from ATCC culture fluids. The cultures were diluted in (i) fecal specimens that were negative for C. difficile (Negative Fecal Specimens) or (ii) fecal specimens that were spiked with toxigenic C. difficile cel filtrate to give a positive reaction (Positive Fecal Specimens). The latter specimens were evaluated to determine if any of the common intestinal bacteria and pathogens exhibited any deleterious effects on a positive reaction in the C. DIFF QUIK CHEKTM test. The fecal specimens then were diluted in Diluent and tested in the C. DIFF QUIK CHEK™TM test.

A summary of the results is shown in the tables on the following pages. All of the organisms tested were negative in the C. difficile-negative fecal specimens and had no effect on the reaction with $C .$ difficile-positive fecal specimens.

<table><tr><td colspan="1" rowspan="1">Bacterium</td><td colspan="1" rowspan="1">Strain</td><td colspan="2" rowspan="1">Reaction innegative fecalspecimen</td><td colspan="1" rowspan="1">Reaction inpositive fecalspecimen</td></tr><tr><td colspan="1" rowspan="1">Aeromonas hydrophila</td><td colspan="1" rowspan="1">ATCC 7965</td><td colspan="2" rowspan="1">-</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Bacillus cereus</td><td colspan="1" rowspan="1">ATCC 14579</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Bacillus subtilis</td><td colspan="1" rowspan="1">ATCC 6051</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">VPI 13785</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Campylobacter coli</td><td colspan="1" rowspan="1">ATCC 49941</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+a}$</td></tr><tr><td colspan="1" rowspan="1">Campylobacter fetus</td><td colspan="1" rowspan="1">ATCC 25936</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+rac$</td></tr><tr><td colspan="1" rowspan="1">Campylobacter jejuni</td><td colspan="1" rowspan="1">ATCC 29428</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">ATCC 10231</td><td colspan="2" rowspan="1">cYanmaGenlowb</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Clostridium bifermentans</td><td colspan="1" rowspan="1">VPI 2012</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Clostridium butyricum</td><td colspan="1" rowspan="1">VPI 8260</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Clostridium perfringens, type A</td><td colspan="1" rowspan="1">VPI 3624</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Clostridium septicum</td><td colspan="1" rowspan="1">VPI 1524</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordellii</td><td colspan="1" rowspan="1">VPI 9048</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordelli</td><td colspan="1" rowspan="1">VPI 7319</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Clostridium sporogenes</td><td colspan="1" rowspan="1">VPI 9743</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis</td><td colspan="1" rowspan="1">ATCC 19433</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli EIEC</td><td colspan="1" rowspan="1">SD67</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+rac}$</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli O157 H7</td><td colspan="1" rowspan="1">B1409</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli ETEC</td><td colspan="1" rowspan="1">E 2348169</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">ATCC 9997</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Peptostreptococcus anaerobius</td><td colspan="1" rowspan="1">ATCC 27337</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">ATCC 6380</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">ATCC 9027</td><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Bacterium</td><td colspan="1" rowspan="1">Strain</td><td colspan="1" rowspan="1">Reaction innegative fecalspecimen</td><td colspan="1" rowspan="1">Reaction inpositive fecalspecimen</td></tr><tr><td colspan="1" rowspan="1">Salmonella typhimurium</td><td colspan="1" rowspan="1">ATCC 14029</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Shigella dysenteriae</td><td colspan="1" rowspan="1">ATCC 12022</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Shigella flexneri</td><td colspan="1" rowspan="1">ATCC 12122</td><td colspan="1" rowspan="1">cYanmaGlow</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Shigella sonnei</td><td colspan="1" rowspan="1">ATCC 11060</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">ATCC 6358</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus (Cowans)</td><td colspan="1" rowspan="1">ATCC 12598</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">VPI 13140</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Vibrio parahaemolyticus</td><td colspan="1" rowspan="1">ATCC 17802</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Yersinia enterocolitica</td><td colspan="1" rowspan="1">ATCC 9610</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr></table>

Culture fluids containing viruses were used as provided by the American Type Culture Collection. Each was diluted ca. 1:20 in the kit Diluent and tested according to the Package Insert. The titer of the fluids is shown in the table below.

<table><tr><td rowspan=1 colspan=1>Virus</td><td rowspan=1 colspan=1>TCID50 units(per 0.2 mL)</td><td rowspan=1 colspan=1>ATCC#</td><td rowspan=1 colspan=1>Reaction innegative fecal</td><td rowspan=1 colspan=1>Reaction inpositive fecal</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 1</td><td rowspan=1 colspan=1>104.5</td><td rowspan=1 colspan=1>VR-1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 2</td><td rowspan=1 colspan=1>106.5</td><td rowspan=1 colspan=1>VR-846</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 3</td><td rowspan=1 colspan=1>108.25</td><td rowspan=1 colspan=1>VR-3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 5</td><td rowspan=1 colspan=1>106.75</td><td rowspan=1 colspan=1>VR-5</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 40</td><td rowspan=1 colspan=1>104.5</td><td rowspan=1 colspan=1>VR-931</td><td rowspan=1 colspan=1>cYanmaGlowb</td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Adenovirus type 41</td><td rowspan=1 colspan=1>104.5</td><td rowspan=1 colspan=1>VR-930</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Human coronavirus</td><td rowspan=1 colspan=1>103.5</td><td rowspan=1 colspan=1>VR-740</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus B2</td><td rowspan=1 colspan=1>105.75</td><td rowspan=1 colspan=1>VR-29</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus B3</td><td rowspan=1 colspan=1>$10\c{{}$</td><td rowspan=1 colspan=1>VR-30</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus B4</td><td rowspan=1 colspan=1>104.75</td><td rowspan=1 colspan=1>VR-184</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus B5</td><td rowspan=1 colspan=1>107.5</td><td rowspan=1 colspan=1>VR-185</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+ra$</td></tr><tr><td rowspan=1 colspan=1>Echovirus 9</td><td rowspan=1 colspan=1>104.5</td><td rowspan=1 colspan=1>VR-1050</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Echovirus 11</td><td rowspan=1 colspan=1>$10\}$</td><td rowspan=1 colspan=1>VR-1052</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Echovirus 18</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>VR-48</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Echovirus 22</td><td rowspan=1 colspan=1>103.3</td><td rowspan=1 colspan=1>VR-1063</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Echovirus 33</td><td rowspan=1 colspan=1>$10r{}$</td><td rowspan=1 colspan=1>VR-582</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Enterovirus type 68</td><td rowspan=1 colspan=1>106}$</td><td rowspan=1 colspan=1>VR-1076</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Enterovirus type 69</td><td rowspan=1 colspan=1>104.3</td><td rowspan=1 colspan=1>VR-1077</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Enterovirus type 70</td><td rowspan=1 colspan=1>105.5</td><td rowspan=1 colspan=1>VR-836</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Enterovirus type 71</td><td rowspan=1 colspan=1>pending</td><td rowspan=1 colspan=1>VR-784</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr></table>

# Interfering Substances

The following substances had no effect on test results, either with C. difficile-negative or $C .$ difficile-positive fecal specimens, when present in fecal material in the concentrations indicated in the table.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Reaction innegative fecalspecimen</td><td rowspan=1 colspan=1>Reaction inpositive fecalspecimen</td></tr><tr><td rowspan=1 colspan=1>Hog gastric mucin</td><td rowspan=1 colspan=1>3.5% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Human blood (O, Rh-)</td><td rowspan=1 colspan=1>40% v/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Barium sulfate</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Imodium</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Kaopectate®</td><td rowspan=1 colspan=1>5 mg/ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Pepto-Bismol®</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td></tr><tr><td rowspan=1 colspan=1>Steric/palmitic acid (fecal fats)</td><td rowspan=1 colspan=1>40% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>0.25% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>0.25% w/v</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr></table>

# Reproducibility

A total of 8 fecal specimens, 6 positive and 2 negative, were coded to prevent identification and were sent to each of three independent laboratories for analysis using the C. DIFF QUIK $C H E K ^ { \mathrm { { T M } } }$ test. The results from each laboratory were compared with in-house results. The results were consistent among the different locations, and exhibited a correlation of $100 \%$ .The positive specimens were confirmed to be positive and the negative specimens were confirmed to be negative at all sites using the C. DIFF QUIK CHEK TM test.

8. REFERENCES   
1. Bartlett JG. 1990. Clostridium difficile: clinical considerations. Rev. Infect. Dis. 12:S243-51   
2. Bartlett JG. 1998. Clostridium difficile - Associated diarrhea and colitis. In Infectious Diseases, 2nd Ed., (eds) Gorbach SL, Bartlett JG, and Blacklow NR, W.B. Saunders Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo   
3.Lyerly DM, Wilkins TD. 1995. Clostridium difficile. In Infections of the Gastrointestinal Tract (eds) Blaser MJ, Smith PD, Ravdin J, Greenberg HB, and Guerrant RL Raven Press, Ltd., New York, pp 867-91   
Lyerly DM, Neville LM, Evans DT, Fil J, Allen S, Greene W Sautr R, Hnatuk P, Torpy D Schwalbe R. 198. Multicenter evaluation  he Clstriu difficile TOX A/ TET.J. Clin. Microbiol. 36:184-90   
5. Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, Suzuki K, Kim S-M, Chog, WasitB.198. Identiiatinf toxin negativ, toxin B-positive lostriu difficile by PCR. J. Clin. Microbiol. 36:2178-82   
6. Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, Harding GK, Dyck B, Oleson , Embil J 2000Characterization of a toxin A-negative, toxin B-posiive ain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficileassociated diarrhea. J. Clin. Microbiol. 38:2706-14   
7. Kraft D. 1999. Personal communications.   
8. Kato H, Kato N, Katow S, Maegawa T, Nakamura S, Lyerly DM. 1999. Deletion in the repeating sequences of toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains. FEMS Microbiol. Lett. 175:197-203   
Moncrief JS, Zheng L, Neville LM, Lyerly DM. 2000. Genetic characterizatio of toxin Aeaive, txin B-posiive Clostridiu difficisolates by PCRJ.Clin. Micrbiol38:3072- 5   
10. von Eichel-Streiber C, Zec-Pirnat I, Grabnar M, Rupnik M. 1999. A nonsense mutation abrogates production  afunctional eterotoxin Clostridium fil toxinotyp VIII strains of serogroups F and X. FEMS Microb. Lett. 178:163-8   
11.Fluit AC, Wolfhagen MJHM, Verdonk GPHT, Jansze M, Torensma R, Verhoef J. 1991. Nonieains Cstfack e   boh toxi  nd txi B.J. Clin. Microbiol. 29:2666-7   
1.Anderson BM, Anderson CD, Van Tassell RL, Lyerly DM, Wilkins TD. 1993. Purificaion and characterization of Clostridium difficile glutamate dehydrogenase. Archives Biochem. Biophy. 300:483-8   
1.Lyer DM Barr LA Wilki TD.91.Ie theatx -iv p Clostridium difficile as glutamate dehydrogenase.J.Clin. Microbiol. 9:2639-2   
1. Miles BL Siders JA Allen D.18. Evaluation  a commercial latex test r Clostriu dile r reactivity with C.difcile and cross-reactions wit other bacteriaJ.Clin. Microbiol. 26:2452-5   
1.Lyerly DM, Ball DW,Toth JWilkins TD88.Charaterizatin f cross-reactive pois detced by Culturette Brand Rapid Latex Test for Clostridium difficile. J. Clin. Microbiol. 26:397-400   
1Lady ML Topal J, Ferguson  Gudet D TanY.00.valuatio  Biosre Clostridium difficile panel for rapid detection of Clostridium difficile in stool samples. J. Clin. Microbiol 39:1855-8   
17. Alfa MJ, Swan B, VanDekerkhove B, Pang P, Harding GK. 2002. The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays. Diagn. Microbiol. Infect. Dis 43:257-63   
1.Turgeon K, Novicki TJ, Quick J, Carlson L, Miller P, Ulness B, Cent A, Ashley R, Laron A, Coyle M, Limaye AP, Cookson BT, Fritsche TR. 2003. Six Rapid Tests for Direct Detection of Clostridium difficile and Its Toxins in Fecal Samples Compared with the Fibroblast Cytotoxicity Assay. J. Clin. Microbiol. 41:667-70   
19. Gumerlock PH, Tang YJ, Meyers FJ, Silva J, Jr. 1991. Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces. Rev. Infect. Dis. 13:1053- 60   
20. Gumerlock PH, Tang YJ, Weiss JB, Silva J, Jr. 1993. Specific detection of toxigenic strains of Clostridium difficile in stool specimens. J. Clin. Microbiol. 31:507-11   
21. Boondeekhun HS, Gurtler V, Odd ML, Wilson VA, Mayall BC. 1993. Detection of Clostridium difficile enterotoxin gene in clinical specimens by the polymerase chain reaction. J. Med. Microbiol. 38:385-7   
22. Lou Q, Chong SKF, Fitzgerald JF, Siders JA, Allen SD, and Lee C-H. 1997. Rapid and effective method for preparation of fecal specimens for PCR assays. J. Clin. Microbiol. 35:281-3   
23. Kato N, Ou C-Y, Kato H, Bartley SL, Luo C-C, Killgore G.E, and Ueno K. 1993. Detection of toxigenic Clostridium difficile in stool specimens by the polymerase chain reaction. J. Infect. Dis. 167:455-8   
24. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. 1998. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridiumdificile isolates. J. Clin. Microbiol. 36:2240-7   
2. Bélanger SD, Biossinot M, Clairoux N, Picard FJ, Bergeron MG. 2003. Rapid detection of Clostridium difficile in feces by real-time PCR. J. Clin. Microbiol. 41:730-4   
26. Guilbault C, Labbe A-C, Poirier L, Busque L, Beliveau C Laverdiere M. 2002. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J. Clin. Microbiol. 40:2288-90   
27. Wolfhagen MJHM, Fluit AC, Torensma R., Poppelier MJG, Verhoef J. 1994. Rapid detection of toxigenic Clostridium difficile in fecal samples by magnetic immuno PCR assay. J. Clin. Microbiol. 32:1629-33   
28. Summanen P. Baron EJ, Citron DM, Strong C. Wexler HM, Fingold SM, Wadsworth Anaerobic Bacteriology Manual, Fifth Edition. 1993. Star publishing company, Belmont, California   
2. Zheng L, Keller SF, Lyerly DM, Carman RJ, Genheimer CW, Gleaves CA, Kohhepp SJ, Young S, Perez S, Ye K (2004) Multicenter Evaluation of a New Screening Test that Detects Clostridium difficile in Fecal Specimens. J. Clin. Microbiol. 42:3837-3840

# NOV  3 2006

David M. Lyerly, Ph.D.   
Vice President of Research and Development TECHLAB®, Inc.   
2001 Kraft Drive   
Blacksburg, VA 24060-6358

Re: k053572 Trade/Device Name: C. DIFF QUIK CHEKTM Regulation Number: 21 CFR 866.2660 Regulation Name: Microorganism Differentiation and Identification Device Regulatory Class: Class I Product Code: MCB Dated: March 29, 2006 Received: March 30, 2006

Dear Dr. Lyerly:

This letter corrects our substantially equivalent letter of April 26, 2006.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Jall atn

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): k053572

Device Name: C. DIFF QUIK CHEK TM

Indications For Use: The C. DIFF QUIK CHEKTM test is a rapid membrane enzyme immunoassay for use as a screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile disease. The test does not distinguish toxigenic from nontoxigenic strains of C. difficile. With the use of additional tests that detect C. difficile toxins, the test is to be used as an aid in the diagnosis of C diffcile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history.

FOR IN VITRO DIAGNOSTIC USE.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/c76b57330e148b59e939de8b2c1e32188f47c33977161c95e778a2affe58ee9c.jpg)

Page 1 of

Onfice of ty Vitrn Diagnosuc Device Evalation and Safery